About Victory Pharma, Inc.
Formed in 2003, Victory Pharma, Inc. acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions.
Brief History
From its inception, Victory's strategy has focused on acquiring and developing products to generate significant sales and build a strong financial base and commercial infrastructure. As the Company evolved, an intellectual property platform was acquired which is suitable for multiple pain therapy development programs. These programs are now being advanced into clinical trials. Today, Victory has transformed into a high-growth pain specialty pharmaceutical firm. Victory's experienced management team is comprised of successful executives from specialty drug ventures such as Dura Pharmaceuticals and DJ Pharma.
Corporate Strategy
Victory is focused on opportunities within the large and expanding pain markets. The Company's current product portfolio consists of marketed products and development-stage product candidates. Due to increased product offerings from recent acquisitions, the company's sales force is expanding to promote these products to a select group of physicians.
The Pain Market
The field of pain management is growing rapidly. According to Jain PharmaBiotech, the worldwide analgesic market was calculated to be worth $50 billion during the year 2005 and is expected to increase to $75 billion by the year 2010.
Many factors drive the growth of pain management, making this a robust market segment for the Company. The following reasons offer promising evidence that ensure Victory’s continued success:
Please see our Privacy Statement.
Formed in 2003, Victory Pharma, Inc. acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions.
Brief History
From its inception, Victory's strategy has focused on acquiring and developing products to generate significant sales and build a strong financial base and commercial infrastructure. As the Company evolved, an intellectual property platform was acquired which is suitable for multiple pain therapy development programs. These programs are now being advanced into clinical trials. Today, Victory has transformed into a high-growth pain specialty pharmaceutical firm. Victory's experienced management team is comprised of successful executives from specialty drug ventures such as Dura Pharmaceuticals and DJ Pharma.
Corporate Strategy
Victory is focused on opportunities within the large and expanding pain markets. The Company's current product portfolio consists of marketed products and development-stage product candidates. Due to increased product offerings from recent acquisitions, the company's sales force is expanding to promote these products to a select group of physicians.
The Pain Market
The field of pain management is growing rapidly. According to Jain PharmaBiotech, the worldwide analgesic market was calculated to be worth $50 billion during the year 2005 and is expected to increase to $75 billion by the year 2010.
Many factors drive the growth of pain management, making this a robust market segment for the Company. The following reasons offer promising evidence that ensure Victory’s continued success:
- A marketplace that is largely dissatisfied with the existing pain-relief products
- Increased patient demand for pain relief
- An aging population with growing pain-relief needs
- Growing acceptance of aggressive pain treatment
- Favorable market reception to new delivery methods and product combinations
Please see our Privacy Statement.
©2007 Victory Pharma, Inc. All Rights Reserved. 1-866-427-6819
